Predictors of High Sputum Eosinophils in Chronic Obstructive Pulmonary Disease.
chronic obstructive pulmonary disease
copd
high sputum eosinophils
Journal
Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
pubmed:
8
7
2022
medline:
8
7
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
Eosinophils are involved in the development of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroid responsiveness. We evaluated clinical predictors of high sputum eosinophil levels in a COPD cohort in China. We conducted an observational, prospective, population-based, cross-sectional study. Participants were tested for COPD and underwent spirometry, computed tomography scans, and a blood test. Participants also produced induced sputum and responded to an information-gathering questionnaire. High sputum eosinophils were defined as ≥3.0%. Multivariate logistic regression was used to identify predictors of high sputum eosinophil levels. We recruited 895 patients with complete and quality control data. The median percentage of sputum eosinophil abundance was 2.00% (interquartile range: 0.75-5.00) and the prevalence of COPD with high sputum eosinophils was 38.0%. Covariance analysis indicated that the high sputum eosinophil group had lower lung function, more severe emphysema, and air trapping. Multivariate logistic regression indicated that high blood eosinophil levels, severe respiratory symptoms, being a former smoker, and a family history of respiratory diseases were associated with high sputum eosinophil levels. High blood eosinophil levels, severe respiratory symptoms, being a former smoker, and a family history of respiratory diseases may be predictors of high sputum eosinophil levels in Chinese COPD patients. High sputum eosinophils were associated with lower lung function, more emphysema, and gas trapping.
Sections du résumé
Background
UNASSIGNED
Eosinophils are involved in the development of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroid responsiveness. We evaluated clinical predictors of high sputum eosinophil levels in a COPD cohort in China.
Methods
UNASSIGNED
We conducted an observational, prospective, population-based, cross-sectional study. Participants were tested for COPD and underwent spirometry, computed tomography scans, and a blood test. Participants also produced induced sputum and responded to an information-gathering questionnaire. High sputum eosinophils were defined as ≥3.0%. Multivariate logistic regression was used to identify predictors of high sputum eosinophil levels.
Results
UNASSIGNED
We recruited 895 patients with complete and quality control data. The median percentage of sputum eosinophil abundance was 2.00% (interquartile range: 0.75-5.00) and the prevalence of COPD with high sputum eosinophils was 38.0%. Covariance analysis indicated that the high sputum eosinophil group had lower lung function, more severe emphysema, and air trapping. Multivariate logistic regression indicated that high blood eosinophil levels, severe respiratory symptoms, being a former smoker, and a family history of respiratory diseases were associated with high sputum eosinophil levels.
Conclusion
UNASSIGNED
High blood eosinophil levels, severe respiratory symptoms, being a former smoker, and a family history of respiratory diseases may be predictors of high sputum eosinophil levels in Chinese COPD patients. High sputum eosinophils were associated with lower lung function, more emphysema, and gas trapping.
Identifiants
pubmed: 35797445
doi: 10.15326/jcopdf.2022.0310
pmc: PMC9448012
doi:
Types de publication
Journal Article
Langues
eng
Pagination
413-426Subventions
Organisme : National Key Research and Development Program
ID : 2016YFC1304101
Pays : China
Organisme : Guangdong Pearl River Talents Program
ID : 2017BT01S155
Pays : China
Organisme : National Natural Science Foundation of China
ID : 81970045
Pays : China
Organisme : Zhongnanshan Medical Foundation/Guangdong Province
ID : ZNSA-2020003
Pays : China
Organisme : Zhongnanshan Medical Foundation/Guangdong Province
ID : ZNSA-2020012
Pays : China
Organisme : Zhongnanshan Medical Foundation/Guangdong Province
ID : ZNSA-2020013
Pays : China
Informations de copyright
JCOPDF © 2022.
Références
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
Eur Respir J. 2022 Jan 13;59(1):
pubmed: 34172466
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Can Respir J. 2013 Nov-Dec;20(6):424-5
pubmed: 24083301
Mayo Clin Proc. 2018 Oct;93(10):1488-1502
pubmed: 30286833
N Engl J Med. 2004 Jun 24;350(26):2645-53
pubmed: 15215480
Lancet. 2015 Mar 7;385(9971):899-909
pubmed: 25123778
Respir Med. 2016 Mar;112:88-96
pubmed: 26872700
JAMA Intern Med. 2015 Sep;175(9):1539-49
pubmed: 26098755
Chest. 2016 Feb;149(2):413-425
pubmed: 26513112
Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204
pubmed: 30592902
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Lancet. 2002 Nov 30;360(9347):1715-21
pubmed: 12480423
COPD. 2005 Jun;2(2):277-83
pubmed: 17136954
J Thorac Dis. 2021 Dec;13(12):6924-6935
pubmed: 35070376
Eur Respir J. 2005 Jun;25(6):986-91
pubmed: 15929952
Am J Respir Crit Care Med. 2017 Aug 1;196(3):306-314
pubmed: 28267373
Eur Respir J. 2014 Oct;44(4):873-84
pubmed: 24993906
Int J Chron Obstruct Pulmon Dis. 2018 Oct 31;13:3589-3596
pubmed: 30464441
J Vis Exp. 2017 Dec 17;(130):
pubmed: 29286433
Parasit Vectors. 2012 Oct 04;5:221
pubmed: 23036110
Eur Respir J. 2014 Dec;44(6):1697-700
pubmed: 25323230
Am J Respir Crit Care Med. 2019 Jan 1;199(1):P1-P2
pubmed: 30592446
Lancet. 2019 Aug 3;394(10196):407-418
pubmed: 31230828
J Cell Mol Med. 2021 Jan;25(2):905-918
pubmed: 33295083
AJR Am J Roentgenol. 2013 Sep;201(3):W460-70
pubmed: 23971478
Thorax. 2014 Aug;69(8):709-17
pubmed: 24706040
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Am J Respir Crit Care Med. 2007 Oct 15;176(8):753-60
pubmed: 17575095
N Engl J Med. 2006 Jul 6;355(1):21-30
pubmed: 16822993
Lancet Respir Med. 2019 Sep;7(9):745-756
pubmed: 31281061
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Allergy Clin Immunol. 2018 Feb;141(2):505-517
pubmed: 29045815
Lancet Respir Med. 2017 Dec;5(12):956-967
pubmed: 29146301
Ann Intern Med. 1987 Feb;106(2):196-204
pubmed: 3492164
Eur Respir J Suppl. 2002 Sep;37:19s-23s
pubmed: 12361358
Int J Chron Obstruct Pulmon Dis. 2020 Aug 25;15:2025-2035
pubmed: 32921998
Int J Chron Obstruct Pulmon Dis. 2021 Aug 28;16:2467-2474
pubmed: 34483658
Infect Dis Poverty. 2020 Nov 30;9(1):164
pubmed: 33256842
Lancet. 2018 Apr 28;391(10131):1706-1717
pubmed: 29650248
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
JAMA. 1999 Oct 6;282(13):1247-53
pubmed: 10517427
BMJ. 2010 Dec 01;341:c6387
pubmed: 21123342
Chest. 2018 Aug;154(2):394-408
pubmed: 29222007
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
Eur Respir J. 2021 May 27;57(5):
pubmed: 33303555
COPD. 2018 Apr;15(2):177-184
pubmed: 29558236
Respirology. 2018 Nov;23(11):1023-1031
pubmed: 29696728
COPD. 2018 Feb;15(1):36-45
pubmed: 29319364
Thorax. 2005 Mar;60(3):193-8
pubmed: 15741434
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74
pubmed: 26641631